PDF(Pubmed)
Abstract：
We present five cases where patients were diagnosed with nonalcoholic steatohepatitis (NASH) and were treated pharmacologically. This is a common disease that is gaining clinical importance due to the long-term sequelae it may bring to a patient, such as cirrhosis, end-stage liver disease, and hepatocellular carcinoma. Diagnosis and treatment are crucial to make a difference in these patients. Diagnosis is mainly through obtaining alanine transaminase (ALT) and aspartate aminotransferase (AST) levels and excluding excessive alcohol use and other identified liver diseases. Diet and lifestyle are the first options in the treatment of NASH, but some pharmacotherapy has been tested for the cure of NASH. Insulin-sensitizing medications, such as Pioglitazone, have shown beneficial effects but with limited success and increase weight as a side effect. The GLP-1 receptor agonist, which are used in diabetes mellitus type two, has shown significant results in patients with NASH such as decreasing ALT levels, body weight, and hepatic fat.
摘要：
我们介绍了5例患者被诊断为非酒精性脂肪性肝炎（NASH）并接受药物治疗的病例。这是一种常见疾病，由于可能给患者带来长期后遗症，因此越来越重要。比如肝硬化，终末期肝病,和肝细胞癌。诊断和治疗对于改变这些患者至关重要。诊断主要是通过获得丙氨酸转氨酶（ALT）和天冬氨酸转氨酶（AST）水平，并排除过度饮酒和其他明确的肝病。饮食和生活方式是治疗NASH的首选，但是一些药物疗法已经过测试，可以治愈NASH。胰岛素增敏药物,比如吡格列酮,已显示出有益的效果，但成功有限，并增加体重作为副作用。GLP-1受体激动剂，用于2型糖尿病，在NASH患者中显示出显著的结果，如ALT水平降低，体重,和肝脏脂肪。
